SA
VRNA

Shilanski & Associates’s Verona Pharma VRNA Stock Holding History

Shilanski & Associates’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,658
Closed -$630K – 136
2025
Q2 		$630K Sell
6,658
-35
-0.5% -$2.59K 0.18% 63
2025
Q1 		$425K Buy
6,693
+117
+2% +$7K 0.13% 67
2024
Q4 		$305K Buy
+6,576
New +$247K 0.1% 82

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Shilanski & Associates's VRNA Position: Q3 2025 in Review

Shilanski & Associates sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 6,658 shares — an estimated $630K sold.

Shilanski & Associates first reported a position in VRNA in Q4 2024 and held it in 3 quarters. The position peaked at $630K in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Shilanski & Associates reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Shilanski & Associates sold 6,658 Verona Pharma shares in Q3 2025, an estimated $630K.
  • Shilanski & Associates first reported a position in Verona Pharma in Q4 2024 and held it in 3 quarters.
  • Shilanski & Associates's Verona Pharma position peaked at $630K in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Shilanski & Associates's 13F filing for Q3 2025, filed 20 Oct 2025.